Associations between each of these recommendations and BC risk (Romaguera et al., 2012; Hastert et al., 2013; Catsburg et al., 2014; Thomson et al., 2014), across tumor subtypes, and considering hormonal receptors and the human epidermal growth factor receptor 2 (HER2) status (Castello et al., 2015), have yielded encouraging results. Here, ERBB2 is linked to neoplasm.